Asceneuron

Asceneuron is developing new chemical entities designed to halt abnormal protein aggregation in the brain, which is a unifying feature of all neurodegenerative diseases.

The page presents a report on clinical advances in tau modifiers, including the clinical O-GlcNAcase inhibitor ASN120290, following a presentation at the 2017 AD/PD Conference in Vienna.

The page states that only a quarter of countries have a national dementia policy, strategy, or plan. Half of these countries are in WHO’s European Region, where many plans are expiring or have expired.

Lausanne, SWITZERLAND and San Francisco, CA, USA, 16 July 2021 – Asceneuron SA, a clinical stage company dedicated to targeting the root cause of neurodegenerative diseases, announced today the appointment of Catherine Moukheibir to its Board of Directors.

Presenting at The Peter Davies Memorial Symposium: The Future of Tau Based Therapies

Findings published in the peer-reviewed journal ACS Chemical Neuroscience demonstrated increased survival in preclinical model of Alzheimer’s disease after administration of clinical molecule ASN90, as well as significant motor impairment and astrogliosis effect in a Parkinson’s model

OGA inhibitors offer multimodal mechanism of action with potential for multiple approaches to clinical development in Alzheimer’s and Parkinson’s disease

Asceneuron is a privately held company financed by a strong syndicate of investors.

The company develops oral therapies to halt abnormal protein aggregation in chronic neurologic diseases.

Route de Crassier 7 CH-1262 Eysins Switzerland

Asceneuron discovers and develops groundbreaking therapeutics for neurodegenerative disorders with high unmet medical needs: orphan tauopathies, Alzheimer’s and Parkinson’s diseases.

This privacy statement was last updated on July 8, 2024 and applies to citizens and legal permanent residents of the European Economic Area and Switzerland.

Asceneuron says it aims to keep its website accurate and up to date and provides an email address for reporting errors.

This imprint was last updated on July 8, 2024.